Special Drug Use Surveillance of Irribow Tablets and Irribow OD Tablets in Female Patients

Trial Profile

Special Drug Use Surveillance of Irribow Tablets and Irribow OD Tablets in Female Patients

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Ramosetron (Primary)
  • Indications Irritable bowel syndrome
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 24 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 27 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top